↓ Skip to main content

Cochrane Database of Systematic Reviews

Aspirin for vascular dementia

Overview of attention for article published in Cochrane database of systematic reviews, October 2000
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
1 news outlet
twitter
16 X users
wikipedia
4 Wikipedia pages

Citations

dimensions_citation
57 Dimensions

Readers on

mendeley
157 Mendeley
Title
Aspirin for vascular dementia
Published in
Cochrane database of systematic reviews, October 2000
DOI 10.1002/14651858.cd001296
Pubmed ID
Authors

Gianetta Rands, Martin Orrell

Abstract

For patients with a diagnosis of vascular dementia there is evidence that aspirin is widely prescribed - in one study, completed by geriatricians and psychiatrists in the UK, 80% of patients with cognitive impairment (with vascular risk factors) were prescribed aspirin. However, a number of queries remain unanswered: Is there convincing evidence that aspirin benefits patients with vascular dementia? Does aspirin affect cognition or improve prognosis? In addition, does the risk of cerebral or gastric haemorrhage outweigh any benefit? To assess the evidence of effectiveness of the use of aspirin for vascular dementia. Computerized databases were searched independently by two reviewers. In addition, relevant websites were searched and some journals were handsearched. Specialists in the field were approached for unpublished material and any publications found were searched for additional references. The most recent search for trials was carried out in February 2000. All randomized controlled trials investigating the effect of aspirin for vascular dementia are included. Inclusion/exclusion of studies comprised systematic assessment of the quality of study design and the risk of bias. Data were extracted independently by both reviewers, using a previously tested data extraction form and, where required, authors were contacted for data not provided in the papers. The aim is to evaluate data recorded via tools assessing cognitive and behavioural changes along with mortality, morbidity and institutionalization data. No trials are eligible for inclusion in this review. There is no evidence that aspirin is effective in treating patients with a diagnosis of vascular dementia. Further research is needed to assess the effect of aspirin on cognition, and on other outcomes such as behaviour, and quality of life. At present there is no evidence relating to other queries about the use of aspirin for dementia (these are described in the Background section of this review). The most recent search for references to relevant research was carried out in February 2000, but no new evidence was found.

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 157 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
United States 1 <1%
Argentina 1 <1%
Unknown 154 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 14%
Student > Master 19 12%
Student > Bachelor 18 11%
Researcher 12 8%
Student > Postgraduate 9 6%
Other 26 17%
Unknown 51 32%
Readers by discipline Count As %
Medicine and Dentistry 44 28%
Psychology 11 7%
Nursing and Health Professions 9 6%
Agricultural and Biological Sciences 8 5%
Social Sciences 6 4%
Other 20 13%
Unknown 59 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 September 2023.
All research outputs
#1,666,716
of 24,157,645 outputs
Outputs from Cochrane database of systematic reviews
#3,753
of 12,850 outputs
Outputs of similar age
#1,151
of 40,434 outputs
Outputs of similar age from Cochrane database of systematic reviews
#3
of 29 outputs
Altmetric has tracked 24,157,645 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,850 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.9. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 40,434 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.